[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].

Seventeen patients aged 26-52 with recurrent thromboembolism of the veins and disturbances of cerebral and coronary circulation (3 and 2 cases, respectively) treated by unfractionated heparin developed thrombocytopenia in the presence of enhanced platelet aggregation. Despite heparin therapy, fresh thrombi of different sites appeared in 5 patients. A cross to fraxiparin (France) resulted in correction of thrombocytopenia, normalization of spontaneous platelet aggregation in two thirds of the patients. In 5 patients thrombocytopenia persisted. It is stated that in most cases low-molecular heparin allows continuation of antithrombotic therapy in heparin-induced thrombocytopenia. Neither transplacental passage nor hemostatic abnormalities in the newborns were recorded after administration of fraxiparin to 6 pregnant women.